Impact on in-hospital outcomes with drug-eluting stents versus bare-metal stents (from 665,804 procedures)
- PMID: 25439448
- DOI: 10.1016/j.amjcard.2014.08.033
Impact on in-hospital outcomes with drug-eluting stents versus bare-metal stents (from 665,804 procedures)
Abstract
Contemporary large-scale data, regarding in-hospital outcomes depending on the types of stent used for percutaneous coronary intervention (PCI) is lacking. We queried the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample from 2006 to 2011 using the International Classification of Diseases, Ninth Revision, Clinical Modification procedure code 36.06 (bare-metal coronary artery stent, BMS) or 36.07 (drug-eluting coronary artery stent, DES) for PCI. All analyses were performed using the designated weighting specified to the Nationwide Inpatient Sample database to minimize bias. Primary outcome was in-hospital mortality. Wald's chi-square test was used for categorical variables. We built a hierarchical 2 level model adjusted for multiple confounding factors, with hospital identification incorporated as random effects in the model and propensity match analyses were used to adjust confounding variables. A total of 665,804 procedures were analyzed, which were representative of 3,277,884 procedures in the United States. Use of bare-metal stents (BMS) was associated with greater occurrence of in-hospital mortality compared with that of drug-eluting stents (DES; 1.4% vs 0.5%, p <0.001). The association stayed significant after adjustment of various possible confounding factors (odds ratio for DES versus BMS 0.59 [0.54 to 0.64, p <0.001]) and also in propensity matched cohorts (1.2% vs 0.7%, p <0.001). The results continued to be similar in the following high-risk subgroups: diabetes (0.57 [0.50 to 0.64, <0.001]), acute myocardial infarction and/or shock (0.53 [0.49 to 0.57, <0.001]), age >80 (0.66 [0.58 to 0.74, <0.001]), and multivessel PCI (0.55 [0.46 to 0.66, <0.001]). In conclusion, DES use was associated with lesser in-hospital mortality compared with BMS. This outcome benefit was seen across subgroups in various subgroups including elderly, diabetics, and acute myocardial infarction as well as multivessel interventions.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.Arch Cardiovasc Dis. 2013 Nov;106(11):554-61. doi: 10.1016/j.acvd.2013.06.056. Epub 2013 Nov 11. Arch Cardiovasc Dis. 2013. PMID: 24231052
-
In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1127-36. doi: 10.1002/ccd.24352. Epub 2012 May 4. Catheter Cardiovasc Interv. 2012. PMID: 22431166
-
In-hospital and one year outcomes with drug-eluting versus bare metal stents in large native coronary arteries: a report from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E356-64. doi: 10.1002/ccd.24451. Epub 2013 May 25. Catheter Cardiovasc Interv. 2013. PMID: 22511502
-
The cost-effectiveness of drug-eluting stents: a systematic review.CMAJ. 2007 Jan 16;176(2):199-205. doi: 10.1503/cmaj.061020. Epub 2006 Dec 19. CMAJ. 2007. PMID: 17179219 Free PMC article. Review.
-
[Percutaneous coronary interventions : Use between 2004 and 2012 in Germany].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Jun;59(6):783-8. doi: 10.1007/s00103-016-2352-5. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016. PMID: 27188620 Review. German.
Cited by
-
Evaluation of safety and efficacy of NexGen - an ultrathin strut and hybrid cell design cobalt-chromium bare metal stent implanted in a real life patient population - the Polish NexGen Registry.Postepy Kardiol Interwencyjnej. 2016;12(3):217-23. doi: 10.5114/aic.2016.61642. Epub 2016 Aug 19. Postepy Kardiol Interwencyjnej. 2016. PMID: 27625684 Free PMC article.
-
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. JAMA. 2015. PMID: 25781440 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
